# A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

Source: https://onco.cc/trials/nct06390995/  
OnCo record `nct06390995` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Mirvetuximab soravtansine in ovarian cancer, run by Takeda, active and no longer recruiting.

## Summary

A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors is a phase 1/2 interventional study registered as NCT06390995 by Takeda, with 28 participants enrolled, started 2024-05-20 and due to reach its primary completion in 2025-04-16. Interventions recorded: TAK-853. Conditions listed: Ovarian Cancer, Solid Tumors. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06390995
- Phase: 1/2
- Setting: A Phase 1/2 Open-label Study to Evaluate The Safety, Tolerability, Efficacy And Pharmacokinetics of Mirvetuximab Soravtansine (TAK-853) in Japanese Patients With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
- Sponsor: Takeda
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT06390995: https://clinicaltrials.gov/study/NCT06390995

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/nct06390995.json